These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 11032907)

  • 1. Tissue plasminogen activator requires plasminogen to modulate amyloid-beta neurotoxicity and deposition.
    Tucker HM; Kihiko-Ehmann M; Wright S; Rydel RE; Estus S
    J Neurochem; 2000 Nov; 75(5):2172-7. PubMed ID: 11032907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impacts of aging and amyloid-β deposition on plasminogen activators and plasminogen activator inhibitor-1 in the Tg2576 mouse model of Alzheimer's disease.
    Bi Oh S; Suh N; Kim I; Lee JY
    Brain Res; 2015 Feb; 1597():159-67. PubMed ID: 25454795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The plasmin system is induced by and degrades amyloid-beta aggregates.
    Tucker HM; Kihiko M; Caldwell JN; Wright S; Kawarabayashi T; Price D; Walker D; Scheff S; McGillis JP; Rydel RE; Estus S
    J Neurosci; 2000 Jun; 20(11):3937-46. PubMed ID: 10818128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The tissue plasminogen activator-plasminogen proteolytic cascade accelerates amyloid-beta (Abeta) degradation and inhibits Abeta-induced neurodegeneration.
    Melchor JP; Pawlak R; Strickland S
    J Neurosci; 2003 Oct; 23(26):8867-71. PubMed ID: 14523088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urokinase-type plasminogen activator inhibits amyloid-beta neurotoxicity and fibrillogenesis via plasminogen.
    Tucker HM; Kihiko-Ehmann M; Estus S
    J Neurosci Res; 2002 Oct; 70(2):249-55. PubMed ID: 12271474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amyloid-beta-stimulated plasminogen activation by tissue-type plasminogen activator results in processing of neuroendocrine factors.
    Kranenburg O; Gent YY; Romijn EP; Voest EE; Heck AJ; Gebbink MF
    Neuroscience; 2005; 131(4):877-86. PubMed ID: 15749342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beta-amyloid (Abeta) causes detachment of N1E-115 neuroblastoma cells by acting as a scaffold for cell-associated plasminogen activation.
    Kranenburg O; Bouma B; Gent YY; Aarsman CJ; Kayed R; Posthuma G; Schiks B; Voest EE; Gebbink MF
    Mol Cell Neurosci; 2005 Mar; 28(3):496-508. PubMed ID: 15737740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristic response of astrocytes to plasminogen/plasmin to upregulate transforming growth factor beta 3 (TGFbeta3) production/secretion through proteinase-activated receptor-1 (PAR-1) and the downstream phosphatidylinositol 3-kinase (PI3K)-Akt/PKB signaling cascade.
    Maeda S; Nakajima K; Tohyama Y; Kohsaka S
    Brain Res; 2009 Dec; 1305():1-13. PubMed ID: 19765562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The possible role of tissue-type plasminogen activator (tPA) and tPA blockers in the pathogenesis and treatment of Alzheimer's disease.
    Melchor JP; Pawlak R; Chen Z; Strickland S
    J Mol Neurosci; 2003; 20(3):287-9. PubMed ID: 14501010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced clearance of Abeta in brain by sustaining the plasmin proteolysis cascade.
    Jacobsen JS; Comery TA; Martone RL; Elokdah H; Crandall DL; Oganesian A; Aschmies S; Kirksey Y; Gonzales C; Xu J; Zhou H; Atchison K; Wagner E; Zaleska MM; Das I; Arias RL; Bard J; Riddell D; Gardell SJ; Abou-Gharbia M; Robichaud A; Magolda R; Vlasuk GP; Bjornsson T; Reinhart PH; Pangalos MN
    Proc Natl Acad Sci U S A; 2008 Jun; 105(25):8754-9. PubMed ID: 18559859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aβ delays fibrin clot lysis by altering fibrin structure and attenuating plasminogen binding to fibrin.
    Zamolodchikov D; Strickland S
    Blood; 2012 Apr; 119(14):3342-51. PubMed ID: 22238323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonproteolytic neuroprotection by human recombinant tissue plasminogen activator.
    Kim YH; Park JH; Hong SH; Koh JY
    Science; 1999 Apr; 284(5414):647-50. PubMed ID: 10213688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tissue plasminogen activator protects hippocampal neurons from oxygen-glucose deprivation injury.
    Flavin MP; Zhao G
    J Neurosci Res; 2001 Mar; 63(5):388-94. PubMed ID: 11223913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroserpin protects neurons from ischemia-induced plasmin-mediated cell death independently of tissue-type plasminogen activator inhibition.
    Wu J; Echeverry R; Guzman J; Yepes M
    Am J Pathol; 2010 Nov; 177(5):2576-84. PubMed ID: 20864675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue-type plasminogen activator is a neuroprotectant in the mouse hippocampus.
    Echeverry R; Wu J; Haile WB; Guzman J; Yepes M
    J Clin Invest; 2010 Jun; 120(6):2194-205. PubMed ID: 20440070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tissue-type plasminogen activator is a multiligand cross-beta structure receptor.
    Kranenburg O; Bouma B; Kroon-Batenburg LM; Reijerkerk A; Wu YP; Voest EE; Gebbink MF
    Curr Biol; 2002 Oct; 12(21):1833-9. PubMed ID: 12419183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteolysis of highly polysialylated NCAM by the tissue plasminogen activator-plasmin system in rats.
    Endo A; Nagai N; Urano T; Ihara H; Takada Y; Hashimoto K; Takada A
    Neurosci Lett; 1998 Apr; 246(1):37-40. PubMed ID: 9622202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective effect of centipedegrass against Aβ oligomerization and Aβ-mediated cell death in PC12 cells.
    Song Y; Kim HD; Lee MK; Kim MK; Kang SN; Ko YG; Won CK; Kim GS; Lee SS; Bai HW; Chung BY; Cho JH
    Pharm Biol; 2015; 53(9):1260-6. PubMed ID: 25853960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ageing and amyloid-beta peptide deposition contribute to an impaired brain tissue plasminogen activator activity by different mechanisms.
    Cacquevel M; Launay S; Castel H; Benchenane K; Chéenne S; Buée L; Moons L; Delacourte A; Carmeliet P; Vivien D
    Neurobiol Dis; 2007 Aug; 27(2):164-73. PubMed ID: 17566751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brain plasmin enhances APP alpha-cleavage and Abeta degradation and is reduced in Alzheimer's disease brains.
    Ledesma MD; Da Silva JS; Crassaerts K; Delacourte A; De Strooper B; Dotti CG
    EMBO Rep; 2000 Dec; 1(6):530-5. PubMed ID: 11263499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.